Clinical Chemistry · 1992 · 40 citations · 14 references
PharmacyPharmacologyClinical ImmunologyKidney TransplantationTransplant ImmunologyBioanalytical Method ValidationImmunoassay AnalysisImmunosuppressant MonitoringAnalytical Liquid ChromatographyBiasesCyclosporine PharmacokineticsImmunoassay MethodologyImmunoassaysPharmacokinetics In TransplantationPositive Results Bias
In an effort to replace HPLC for whole-blood determination of cyclosporine (CsA), we compared HPLC with radioimmunoassay (RIA; INCSTAR, Cyclo-Trac SP assay), fluorescence polarization immunoassay (FPIA; Abbott TDx), and in-house modified enzyme-multiplied immunoassay technique (EMIT; Syva Co.). For blood samples from 200 various transplant recipients, RIA = 1.262 (HPLC) - 8.16, r = 0.983; FPIA = 1.200 (HPLC) + 19.90, r = 0.981; and EMIT = 1.038 (HPLC) + 11.28, r = 0.985. For segregation by transplant type, RIA, FPIA, and EMIT demonstrated positive biases of 27%, 12%, and 3%, respectively, for liver transplant recipients (n = 50) when compared with HPLC. Heart transplant recipients (n = 50) gave positive bias values of 23%, 14%, and 4% for RIA, FPIA, and EMIT, respectively. Adult renal transplant recipients (n = 50) demonstrated positive bias values of 30%, 31%, and 0% for RIA, FPIA, and EMIT, respectively. For pediatric renal transplant recipients (n = 50), positive biases of 40%, 31%, and 9% were obtained for RIA, FPIA, and EMIT, respectively. We conclude that the modified EMIT represents the best replacement for HPLC.
14
Potential of monoclonal antibodies to improve therapeutic monitoring of cyclosporine.
Valérie Quesniaux, Reet Tees, Max H. Schreier et al. · Clinical Chemistry · 1987 · 54 citations
Pharmacy, Immunology, Pharmacology +16